NCT06914648Recruiting
The Dragon PLC Trial (DRAGON-PLC)
Summary
The goal of the DRAGON PLC clinical trial is to determine whether portal vein embolization (PVE) combined with hepatic vein embolization (HVE) improves resectability and overall survival in patients with initially unresectable primary liver cancer compared to standard PVE alone. This trial specifically focuses on patients with hepatocellular carcinoma and cholangiocarcinoma. The main questions this trial aims to answer are whether combined PVE and HVE increases the proportion of patients who become resectable within 3 weeks and improves 5-year overall survival compared to PVE alone by enhancing liver hypertrophy. Participants will: * Undergo either standard PVE or combined PVE and HVE. * Have regular imaging to assess liver resectability. * Be monitored for survival outcomes up to 5 years after intervention.
Inclusion criteria
• PLC diagnosis, specifically iCCC, pCCC, and HCC; • Requiring PVE due to an FLR volume is \<30% in normally functioning livers, \<40% in livers with potentially impaired function e.g. resulting from prior systemic therapy induction or bile duct colonization / transpapillary biliary drainage, or \<50% in livers with severely impaired function resulting from liver cirrhosis (max. Child Pugh A5) OR function on hepatobiliary scintigraphy (HEBIS) is \< 2.7 %/min/m2; • Age ≥ 18 years; • Able to understand the trial and provide informed consent.
Exclusion criteria
• Liver cirrhosis with a Child-Pugh score of B or C; • Presence of portal hypertension; • Presence of cholangitis; • Pregnant women; • Premenopausal females not able/willing to commit to contraception (specifically long-acting reversible contraception or hormonal contraception); • Patients unresectable due to prohibitive comorbidities (decision made by local multidisciplinary team); • Patients with hepatic malignancies other than iCCC, pCCC or HCC; • PVE/HVE anatomically not feasible; • Any patient with non-resectable or non-ablatable extrahepatic metastatic disease. • Unable to understand the study information, study instructions and give informed consent
Contacts
The trial team's contact details are shown on request.
See the official trial record- Status
- Recruiting
- Phase
- No phase (N/A)
- Study type
- Interventional
- Countries
- Switzerland, Germany, Italy, Austria, United States, Australia, Belgium, Canada, Netherlands, Norway, Sweden, United Kingdom
- Sponsor
- Maastricht University(Other)
- Protocol no.
- NL87590.0681.24
- Conditions
- Primary Liver Cancer, Hepatocellular Carcinoma (HCC), Cholangiocarcinoma
- Interventions
- Procedure
Treatments studied
- Portal Vein Embolization
- Hepatic Vein Embolization
Locations · 1
- Liège, BelgiumCHU LiègeRecruiting at this site
In total, worldwide, 1 of the 55 sites listed in the registry is recruiting; the other 54 are not currently recruiting.
Site status per the ClinicalTrials.gov registry (last update posted: May 15, 2025).
This status may have changed and says nothing about your eligibility: before taking any step, check with your oncologist or the site.
See also
Other versions
These results are indicative and do not replace medical advice — discuss them with your doctor.